Corrigendum to: Development of bispecific antibodies in China: overview and prospects

Jing Zhang, Jizu Yi^b* and Pengfei Zhou*

Wuhan YZY Biopharma Co., Ltd. Biolake City C2-1, No. 666 Gaoxin Road, Wuhan, Hubei 430075, China

Antibody Therapeutics, 2021, doi: https://doi.org/10.1093/abt/tbaa011

In the originally published version of this manuscript, the following conflict of interest statement was omitted: "The authors are employees of Wuhan YZY Biopharma Co., Ltd that develops and commercializes antibody therapeutics including bispecific antibodies."

This has been corrected.

*To whom correspondence should be addressed. Jizu Yi or Pengfei Zhou. Email: yijizu@yzybio.com or pfzhou@yzybio.com.

[©] The Author(s) 2021. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com